Accelerate Diagnostics (NASDAQ:AXDX) Now Covered by StockNews.com

Equities researchers at StockNews.com began coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX) in a research note issued on Thursday. The firm set a “hold” rating on the medical research company’s stock.

Separately, BTIG Research raised Accelerate Diagnostics to a “strong-buy” rating in a research note on Wednesday, December 11th.

Accelerate Diagnostics Price Performance

Shares of NASDAQ AXDX opened at $0.56 on Thursday. The stock has a market capitalization of $14.12 million, a P/E ratio of -0.20 and a beta of 0.46. Accelerate Diagnostics has a one year low of $0.49 and a one year high of $2.09. The firm’s 50 day simple moving average is $1.00 and its two-hundred day simple moving average is $1.35.

Accelerate Diagnostics (NASDAQ:AXDX) last announced its quarterly earnings data on Thursday, March 20th. The medical research company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.13. The business had revenue of $2.82 million during the quarter, compared to analysts’ expectations of $3.00 million. As a group, equities analysts expect that Accelerate Diagnostics will post -2.3 earnings per share for the current fiscal year.

Institutional Trading of Accelerate Diagnostics

A number of institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC purchased a new position in shares of Accelerate Diagnostics in the fourth quarter worth $27,000. Renaissance Technologies LLC grew its holdings in Accelerate Diagnostics by 160.6% in the 4th quarter. Renaissance Technologies LLC now owns 107,062 shares of the medical research company’s stock worth $128,000 after acquiring an additional 65,984 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Accelerate Diagnostics by 6.9% in the fourth quarter. Geode Capital Management LLC now owns 135,732 shares of the medical research company’s stock valued at $163,000 after acquiring an additional 8,777 shares during the period. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of Accelerate Diagnostics during the third quarter valued at about $34,000. Hedge funds and other institutional investors own 17.14% of the company’s stock.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.